These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21858836)

  • 1. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
    Uren RF; Howman-Giles R; Chung D; Thompson JF
    J Surg Oncol; 2011 Sep; 104(4):405-19. PubMed ID: 21858836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
    Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
    J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
    Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
    Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
    Maubec E; Lumbroso J; Masson F; Suciu V; Kolb F; Mamelle G; Cavalcanti A; Boitier F; Spatz A; Aupérin A; Leboulleux S; Avril MF
    Melanoma Res; 2007 Jun; 17(3):147-54. PubMed ID: 17505260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy.
    Nieweg O; Valdés Olmos R
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):602; author reply 603. PubMed ID: 17205347
    [No Abstract]   [Full Text] [Related]  

  • 7. Desmoplastic malignant melanoma evaluated with 18F-fluorodeoxyglucose positron emission tomography-computed tomography and sentinel lymph node biopsy.
    Jung JY; Roh MR; Chung HJ; Chung KY
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):126-7. PubMed ID: 18181996
    [No Abstract]   [Full Text] [Related]  

  • 8. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of lymph node ultrasound and whole body
    Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorodeoxyglucose-PET in the management of malignant melanoma.
    Kumar R; Mavi A; Bural G; Alavi A
    Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of lymphoscintigraphy in the detection of lymph node drainage in melanoma.
    Uren RF; Thompson JF; Howman-Giles R; Chung DK
    Surg Oncol Clin N Am; 2006 Apr; 15(2):285-300. PubMed ID: 16632215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
    Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
    Kumar R; Alavi A
    Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma.
    Singh B; Ezziddin S; Palmedo H; Reinhardt M; Strunk H; Tüting T; Biersack HJ; Ahmadzadehfar H
    Melanoma Res; 2008 Oct; 18(5):346-52. PubMed ID: 18781133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
    Clark PB; Soo V; Kraas J; Shen P; Levine EA
    Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma.
    Thompson JF
    Ann Surg Oncol; 2001 Oct; 8(9 Suppl):44S-47S. PubMed ID: 11599898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study.
    Klein M; Freedman N; Lotem M; Marciano R; Moshe S; Gimon Z; Chisin R
    Nuklearmedizin; 2000; 39(3):56-61. PubMed ID: 10834191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma.
    Havenga K; Cobben DC; Oyen WJ; Nienhuijs S; Hoekstra HJ; Ruers TJ; Wobbes T
    Eur J Surg Oncol; 2003 Oct; 29(8):662-4. PubMed ID: 14511614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Gad D, Hoiland-Carlesen PF, Bartram P, et al.: staging patients with cutaneous malignant melanoma by same day lymphoscintigraphy and sentinel lymph node biopsy: a single-institutional experience with emphasis on recurrence.
    van Rijk MC; Nieweg OE; Kroon BB
    J Surg Oncol; 2006 Aug; 94(2):170-1; author reply 172. PubMed ID: 16847827
    [No Abstract]   [Full Text] [Related]  

  • 20. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.